Canada markets closed

Insmed Incorporated (INSM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
27.48+0.51 (+1.89%)
At close: 04:00PM EST
27.48 0.00 (0.00%)
After hours: 04:27PM EST

Insmed Incorporated

700 US Highway 202/206
Bridgewater, NJ 08807
United States
908 977 9900

Full Time Employees736

Key Executives

NameTitlePayExercisedYear Born
Mr. William H. Lewis J.D., M.B.A.President, CEO & Chairman1.29M6.48M1969
Ms. Sara M. Bonstein M.B.A.Chief Financial Officer684.18kN/A1981
Mr. Roger Adsett M.B.A.Chief Operating Officer894.7kN/A1969
Mr. John Drayton Wise M.B.A.Chief Commercial Officer750kN/AN/A
Dr. Martina Flammer M.B.A., M.D.Chief Medical Officer763.62kN/A1964
Mr. Brian K. Kaspar Ph.D.Chief Scientific OfficerN/AN/A1974
Eleanor BarisserAssociate Director of Investor RelationsN/AN/AN/A
Mr. Michael Alexander Smith J.D.Senior VP, General Counsel & Corporate SecretaryN/AN/A1978
Mandy FaheyExecutive Director of Corporate CommunicationsN/AN/AN/A
Ms. S. Nicole Schaeffer M.B.A.Chief People Strategy Officer660.81k1.18M1968
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis, cystic fibrosis, and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Corporate Governance

Insmed Incorporated’s ISS Governance QualityScore as of December 1, 2023 is 6. The pillar scores are Audit: 6; Board: 5; Shareholder Rights: 9; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.